Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2006-04-17
2008-10-21
Minnifield, N. M (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S184100, C424S185100, C424S192100, C424S265100, C424S268100, C424S272100, C530S300000, C530S350000, C530S324000, C530S325000, C530S326000, C530S344000, C530S822000, C530S820000, C435S004000, C435S007100, C435S007200, C435S007920
Reexamination Certificate
active
07438917
ABSTRACT:
The present invention relates to an in vitro diagnostic method for malaria in an individual comprising placing a tissue or a biological fluid taken from an individual in contact with a molecule or polypeptide composition, wherein said molecule or polypeptide composition comprises one or more peptide sequences bearing all or part of one or more T epitopes of the proteins resulting from the infectious activity ofP. falciparum, under conditions allowing an in vitro immunological reaction to occur between said composition and the antibodies that may be present in the tissue or biological fluid, and in vitro detection of the antigen-antibody complexes formed. The invention further relates to a polypeptide comprising at least one T epitope from a liver-stage specific protein produced byP. falciparumand a vaccine composition directed against malaria comprising a molecule having one or more peptide sequences bearing all or part of one or more T epitopes resulting from the infectious activity ofP. falciparumin the hepatic cells.
REFERENCES:
patent: 5589343 (1996-12-01), Marchand et al.
patent: 5599542 (1997-02-01), Marchand et al.
patent: 5602031 (1997-02-01), Marchand et al.
patent: 5690941 (1997-11-01), Druilhe et al.
patent: 5928901 (1999-07-01), Marchand et al.
patent: 6017538 (2000-01-01), Druilhe et al.
patent: 6191270 (2001-02-01), Druilhe et al.
patent: 6270771 (2001-08-01), Guerin-Marchand et al.
patent: 6319502 (2001-11-01), Guerin-Marchand et al.
patent: 6669945 (2003-12-01), Nardin et al.
patent: 6828416 (2004-12-01), Lal et al.
patent: 7056518 (2006-06-01), Druilhe et al.
patent: 7087231 (2006-08-01), Guerin-Marchand et al.
patent: 7332595 (2008-02-01), Guerin-Marchand et al.
patent: 2002/0041882 (2002-04-01), Guerin-Marchand et al.
patent: 2003/0064075 (2003-04-01), Guerin-Marchand et al.
patent: 2004/0067236 (2004-04-01), Cohen et al.
patent: 2005/0075496 (2005-04-01), Druilhe et al.
patent: 2005/0108791 (2005-05-01), Edgerton
patent: 2005/0266017 (2005-12-01), Druilhe et al.
patent: 2005/0287166 (2005-12-01), Druilhe et al.
patent: 2006/0182769 (2006-08-01), Guerin-Marchand et al.
patent: 2006/0188527 (2006-08-01), Hoffman et al.
patent: 0 407 230 (1991-01-01), None
patent: WO 84/02917 (1984-08-01), None
patent: 86/01802 (1986-03-01), None
patent: WO 86/01802 (1986-03-01), None
patent: WO 86/06075 (1986-10-01), None
patent: WO 87/05607 (1987-09-01), None
patent: 88/05785 (1988-08-01), None
patent: 90/06130 (1990-06-01), None
patent: 92/05193 (1992-04-01), None
patent: 92/13884 (1992-08-01), None
patent: 84/02917 (1994-08-01), None
Rzepczyk et al, J. Immunology, 1988, 141/9:3197-3202.
Russo et al, J. Immunology, 1989, 143/2:655-659.
Calvo-Calle, Dissertation Abstracts International, 2004, 65/9B:4495 abstract only.
Perlaza et al, Eur. J. Immunol., 2001, 31:2200-2209.
BenMohamed et al, Infection and Immunity, 2004, 72/8:4376-4384.
Herbert et al, J. Immunological Methods, 2003, 275:123-132.
Brahimi et al, Infection and Immunity, 2001, 69/6:3845-3852.
Calvo-Calle et al, J. Immunology, 2005, 175:7575-7585.
Taylor-Robinson, Immunologic Research, 2003, 27/1:53-69.
Taylor-Robinson, Expert Rev. Vaccines, 2002, 1/3:317-340.
Hoffman et al, In: Technological Advances in Vaccine Development, 1988, pp. 625-639.
Favaloro et al, Nucleic Acids Research, 1986, 14/21:8265-8277.
Guerin-Marchand, C., et al.,Nature, 1987, 329/6135:164-7, Macmillan Publishers, USA.
Londono, J., et al.,J. Immunol., 1990, 145(5):1557-63, American Association of Immunologists, USA.
Hollingdalte, M., et al.,Chem Abst., 1990, 113:189314w, pp. 534, American Chemical Society, USA.
Marchand, C., et al.,Bulletin of the World Health Organization,1990, 68:158-64.
Favalero, J.M., et al.,Nucl. Acid Res., 1986, 14(1):8265-77, Oxford University Press, Great Britain.
Ben-Mohamed et al.,Eur. J. Immunol., 1997, 27:1242-53, Wiley-VCH Verlag GmbH, Germany.
Sharma, Shobhona, et al., “Diversity of Circumsporozoite Antigen Genes from Two Strains of the Malarial ParasitePlasmodium knowlesi”, Science, Aug. 1985, pp. 779-782, vol. 229, AAAS, Washington, D.C.
Druilhe, P., et al., “Species- and Stage-Specific Antigens in Exoerythrocytic Stages ofPlasmodium falciparum”, Am. J. Trop. Med. Hyg., 1984, pp. 336-341, 33(3), The American Society of Tropical Medicine and Hygiene, US.
Weber, James L., et al., “Primary Structure of aPlasmodium falciparumMalaria Antigen Located at the Merozoite Surface and Within the Parasitophorous Vacuole”,J. Biol. Chem., Aug. 15, 1988, pp. 11421-11425, vol. 263, No. 23, American Society for Biochemistry and Molecular Biology, Baltimore, MD.
Fidock, David A., et al., “Plasmodium falciparumLiver Stage Antigen 1- is Well Conserved and Contains Potent B and T Cell Determinants”,J. Immunol., 1994, pp. 190-204, vol. 153, The American Association of Immunologists, Baltimore, MD.
Zhu, Jingdong, et al., “Structure ofPlasmodium falciparumliver stage antigen-1”,Molecular and Biochemical Parasitology, 1991, pp. 223-226, vol. 48, Elsevier Science Publisher B.V., Amersterdam, The Netherlands.
Shortt, H. E., et al., “The Pre-Erythrocytic Development ofPlasmodium gynomolgiandPlasmodium vivax”, Transactions of the Royal Society of Tropical Medicine and Hygiene., May 1948, pp. 785-795, vol. 41, No. 6, UK.
Roitt, Ivan, et al.,Immunology, 1989, pp. 2.4-2.7, 2ndEdition, Gower Medical Publishing, London, England.
“B cell epitope prediction reviews”,“Other B cell epitope prediction” and “T cell epitopes and prediction”, ePitope Informatics, Prediction and analysis of protein epitopes, http://www.epitope-informatics.com/References.htm.
Margalit, H., et al., “Prediction of immunodominant helper T cell antigenic sites from the primary sequence.”,J Immunol. Apr. 1, 1987;138(7):2213-29.; PMID: 2435793 [PubMed—indexed for Medline]; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list—ui...; Aug. 3, 2004 (Abstract only).
Livingstone, AM, et al., “The structure of T-cell epitopes.”,Annu Rev Immunol. 1987;5:477-501.; PMID: 2439104 [PubMed—indexed for Medline]; http:/www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&db=pubmed&dopt=A...; Aug. 3, 2004 (Abstract only).
Spouge, JL, et al., “Strong conformational propensities enhance T cell antigenicity.”,J Immunol. Jan. 1, 1987;138(1):204-12; PMID: 2431054 [PubMed—indexed for Medline]; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db-PubMed&list—uni... Aug. 3, 2004 (Abstract only).
Jolivet, M., et al., “Polyvalent synthetic vaccines: relationship between T epitopes and immunogenicity.”,Vaccine. Feb. 1990;8(1):35-40.; PMID: 1690488 [PubMed—indexed for Medline]; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list—ui... Aug. 3, 2004 (Abstract only).
Miles, MA, et al., “Cloning of microbial epitopes relevant for T- and B-cells.”,Behring Inst Mitt. Feb. 1991;(88):133-41.; PMID: 1710887 [PubMed—indexed for Medline]; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list—ui... Aug. 3, 2004 (Abstract only) . . . .
Miles, MA, et al., “Cloning of microbial epitopes relevant for T- and B-cells.”,Behring Inst Mitt. Feb. 1991;(88):133-41.; PMID: 1710887 [PubMed—indexed for Medline]; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list—ui... Aug. 3, 2004 (Abstract only).
Feller, DC, “Identifying antigenic T-cell sites.”,Nature. Feb. 21, 1991;349(6311):720-1.; PMID: 1705016 [PubMed—indexed for Medline]; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list—ui... Aug. 3, 2004 (Abstract only).
Van der Zee, R., et al., “Efficient mapping and characterization of a T cell epitope by the simultaneous synthesis of multiple peptides.”,Eur J Immunol. Jan. 1989;19(1):43-7.; PMID: 2465904 [PubMed—indexed for
Druilhe Pierre
Guerin-Marchand Claudine
Crowell & Moring LLP
Institut Pasteur
Minnifield N. M
LandOfFree
Peptide sequences specific for the hepatic stages of P.... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptide sequences specific for the hepatic stages of P...., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptide sequences specific for the hepatic stages of P.... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4013307